Rxsight Inc
NASDAQ:RXST

Watchlist Manager
Rxsight Inc Logo
Rxsight Inc
NASDAQ:RXST
Watchlist
Price: 33.66 USD -11.86% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Rxsight Inc?
Write Note

Rxsight Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Rxsight Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Rxsight Inc
NASDAQ:RXST
Income from Continuing Operations
-$48.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Haemonetics Corp
NYSE:HAE
Income from Continuing Operations
$123.8m
CAGR 3-Years
58%
CAGR 5-Years
13%
CAGR 10-Years
15%
ICU Medical Inc
NASDAQ:ICUI
Income from Continuing Operations
-$111m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Align Technology Inc
NASDAQ:ALGN
Income from Continuing Operations
$441.6m
CAGR 3-Years
-16%
CAGR 5-Years
1%
CAGR 10-Years
12%
Lantheus Holdings Inc
NASDAQ:LNTH
Income from Continuing Operations
$427.6m
CAGR 3-Years
N/A
CAGR 5-Years
65%
CAGR 10-Years
N/A
Merit Medical Systems Inc
NASDAQ:MMSI
Income from Continuing Operations
$120m
CAGR 3-Years
40%
CAGR 5-Years
40%
CAGR 10-Years
19%
No Stocks Found

Rxsight Inc
Glance View

Market Cap
1.4B USD
Industry
Health Care

In the dynamic realm of ophthalmology, RxSight Inc. has carved a niche as a pioneering force in enhancing vision outcomes for cataract patients. At the heart of the company’s innovation is its Light Adjustable Lens (LAL) system. Traditional intraocular lenses (IOLs), once implanted, lock patients into a certain prescription, accepting only minimal adjustments. RxSight, with its groundbreaking technology, offers a solution that breaks this convention. Post-cataract surgery, the LAL allows ophthalmologists to precisely adjust the lens prescription using UV light, often yielding better visual acuity tailored to patient needs. This transformative approach turns the one-size-fits-all model of vision correction into a personalized patient experience, promising a brighter, clearer outlook on life. Commercially, RxSight operates within the medical device industry, focusing on capturing a significant share of the cataract surgery market—one of the most frequent surgeries performed worldwide. The company earns revenue primarily through the sale of its LAL system to eye care professionals and clinics. This business model is akin to a razor-and-blade approach; besides the initial sale of the adjustable lenses, RxSight garners continuous revenue from associated products and services, such as the light delivery device and follow-up adjustments required post-surgery. By addressing a substantial unmet need with a recurring revenue stream, RxSight strategically positions itself for growth within the burgeoning biotech sector, all while setting new benchmarks for patient satisfaction in eye care.

RXST Intrinsic Value
14.51 USD
Overvaluation 57%
Intrinsic Value
Price

See Also

What is Rxsight Inc's Income from Continuing Operations?
Income from Continuing Operations
-48.6m USD

Based on the financial report for Dec 31, 2023, Rxsight Inc's Income from Continuing Operations amounts to -48.6m USD.

What is Rxsight Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 1Y
27%

Over the last year, the Income from Continuing Operations growth was 27%.

Back to Top